Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medipal HoldingsTSE:7459 +0.79%82 3-Year ROIIC % is 3.84 as of Mar. 2026, which is 45% below its 10-year median of 6.98. GuruFocus rates TSE:7459 with a GF Score™ of 82/100 and a GF Value™ of 円2,734.96 (Fairly Valued). The stock has 6 warning signs investors should review. Among 112 Medical Distribution companies, Medipal Holdings ranks better than 55.36% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Medipal Holdings's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 3.84%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Medipal Holdings's 3-Year ROIIC % or its related term are showing as below:
TSE:7459's 3-Year ROIIC % is ranked better than 55.36% of 112
companies
in the Medical Distribution industry
Industry Median: 2.145
vs TSE:7459: 3.84
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Medipal Holdings 3-Year ROIIC % Related Terms
Medipal Holdings 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Medipal Holdings's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7459 vs MCK, CAH, COR: 3-Year ROIIC % Comparison
For the Medical Distribution subindustry, Medipal Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medipal Holdings 3-Year ROIIC % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medipal Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Medipal Holdings's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Medipal Holdings (TSE:7459) has a 3-Year ROIIC % of 3.84 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medipal Holdings and its competitors. This is 45% below median its historical median of 6.98. According to the industry distribution chart, Medipal Holdings ranks #50 out of 112 companies in the Medical Distribution industry, placing it in the top 44.6%.
Is Medipal Holdings' 3-Year ROIIC % too high?
Medipal Holdings' current 3-Year ROIIC % of 3.84 is 45% below median its 10-year median of 6.98. The Medical Distribution industry median 3-Year ROIIC % is 2.15. Medipal Holdings' value of 3.84 is 79% above this industry median. Based on the distribution chart, Medipal Holdings ranks #50 out of 112 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Medipal Holdings has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' 3-Year ROIIC % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #50 out of 112 companies for 3-Year ROIIC %. This puts Medipal Holdings in the upper half of its industry. The industry median 3-Year ROIIC % is 2.15. Medipal Holdings' value of 3.84 is 79% above this benchmark. While the company's 10-year median is 6.98 vs. the industry median of 2.15, Medipal Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.15, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current 3-Year ROIIC % of 3.84 is 79% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medipal Holdings and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current 3-Year ROIIC % is 3.84, which is 45% below median its own 10-year median of 6.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (TSE:7459) is currently considered Fairly Valued. The stock's GF Value™ is 円2,734.96, compared to a current price of 円2,876.50 — trading 5.2% above its estimated fair value. The current 3-Year ROIIC % is 3.84, which is 45% below median its 10-year median of 6.98 and 79% above the Medical Distribution industry median of 2.15. Medipal Holdings' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Medipal Holdings (TSE:7459), the current 3-Year ROIIC % is 3.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (TSE:7459) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued.
The current stock price of 円2,876.50 is trading 5.2% above its estimated GF Value™ of 円2,734.96.
GuruFocus considers Medipal Holdings to be Fairly Valued.
Key valuation signals for TSE:7459:
3-Year ROIIC %: 3.84 (45% below median its 10-year median of 6.98)
GF Value™: 円2,734.96 vs. price of 円2,876.50 (5.2% above fair value)
Industry Position: 79% above the Medical Distribution median (#50 of 112)
No single metric tells the full story. See the TSE:7459 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
82GF Score
Get the complete analysis for TSE:7459
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7459 has been successfully added to your 
